Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European Union’s approval of Ipsen’s Iqirvo, a groundbreaking therapy for primary biliary cholangitis (PBC), a rare liver condition. As the lead investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s team enrolled the very first patient, and he authored the key study results published in the New England Journal of Medicine.
A huge congratulations to Ipsen, Dr. Kowdley, the Seattle team, and all the patients and staff who made this remarkable advancement possible!
Read the full press release: https://www.ipsen.com/press-releases/ipsens-iqirvo-elafibranor-approved-in-the-european-union-as-first-new-treatment-for-primary-biliary-cholangitis-in-nearly-a-decade-2949674/
